Centogene, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, entered into an agreement with Aldeyra Therapeutics Inc., a biotechnology company developing next-generation medicines to improve the lives of patients with immune-mediated diseases.
Under the terms of the agreement, Centogene will collaborate with Aldeyra to globally identify patients with Sjögren-Larsson Syndrome (SLS) and to understand the clinical spectrum of this disease. The goal of the agreeement is to support physicians and patients with early diagnosis through genetic testing that could potentially lead to the identification of novel therapeutic developments and raise awareness of the disease.
SLS is inherited in an autosomal recessive manner and patients display a broad spectrum of symptoms including: ichthyosis (severely dry, thickened, scaly skin), spacisity in the legs and congnitive delay. Patients suffering from SLS cannot properly break down molecules called fatty aldehydes resulting in an abnormal accumulation of these molecules leading to symptoms of the disease.
Aldeyra Therapeutics, based in Burlington (Massachusetts, USA), develops drug candidates for capturing and removing free aldehydes to treat and prevent diseases, and slow the progression of chronic disease. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It develops NS2, a compound that binds and traps free aldehydes.
Headquartered in Rostock, Germany, Centogene AG is a laboratory that focuses on genetic and biochemical diagnostic testing services for rare hereditary disorders for the global medical community. It supports clinicians with genetic counseling services and newborn screening, as well as performs analysis of biomarkers for lysosomal storage disorders.